Rocket Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Rocket Pharmaceuticals, Inc. (RCKT) reported Increase (Decrease) in Accrued Liabilities of -$1.85 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2017-12-31 was $229.00K, a 84.24% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2017-09-30 was -$103.00K, a 110.13% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2017-06-30 was $282.00K.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2017-03-31 was -$2.25M, a 408.77% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2017 was -$1.85M, a 159.32% decline from fiscal 2016.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2016 was $3.11M, a 116.41% increase from fiscal 2015.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2015 was $1.44M.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2014 was -$587.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $126.00K derived: sum of 2 quarters · filed 2018-03-07 | $408.00K derived: sum of 3 quarters · filed 2018-03-07 | -$1.85M 10-K · filed 2018-03-07 |
| 2017-09-30 | -$103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $179.00K derived: sum of 2 quarters · filed 2017-11-08 | -$2.08M 10-Q · filed 2017-11-08 | -$622.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $282.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$1.97M 10-Q · filed 2017-08-03 | -$519.00K derived: sum of 3 quarters · filed 2018-03-07 | $498.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | -$2.25M 10-Q · filed 2017-05-10 | -$801.00K derived: sum of 2 quarters · filed 2018-03-07 | $216.00K derived: sum of 3 quarters · filed 2018-03-07 | $128.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $2.47M derived: sum of 2 quarters · filed 2018-03-07 | $2.38M derived: sum of 3 quarters · filed 2018-03-07 | $3.11M 10-K · filed 2018-03-07 |
| 2016-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $929.00K derived: sum of 2 quarters · filed 2017-11-08 | $1.66M 10-Q · filed 2017-11-08 | $2.61M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $642.00K 10-Q · filed 2017-08-03 | $1.59M derived: sum of 3 quarters · filed 2017-08-03 | $1.43M derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | $730.00K 10-Q · filed 2017-05-10 | $1.68M derived: sum of 2 quarters · filed 2017-05-10 | $1.52M derived: sum of 3 quarters · filed 2017-05-10 | $2.00M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $951.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $787.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.27M derived: sum of 3 quarters · filed 2017-03-16 | $1.44M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $317.00K derived: sum of 2 quarters · filed 2016-11-09 | $487.00K 10-Q · filed 2016-11-09 | $11.00K derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $481.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $651.00K 10-Q · filed 2016-08-10 | $175.00K derived: sum of 3 quarters · filed 2016-08-10 | -$155.00K derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | $170.00K 10-Q · filed 2016-05-11 | -$306.00K derived: sum of 2 quarters · filed 2016-05-11 | -$636.00K derived: sum of 3 quarters · filed 2016-05-11 | -$471.00K derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | -$476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$806.00K derived: sum of 2 quarters · filed 2016-03-23 | -$641.00K derived: sum of 3 quarters · filed 2016-03-23 | -$587.00K 10-K · filed 2016-03-23 |
| 2014-09-30 | -$330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$165.00K derived: sum of 2 quarters · filed 2015-11-12 | -$111.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $219.00K 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $54.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |